iTeos Therapeutics (ITOS)
(Delayed Data from NSDQ)
$10.13 USD
+0.02 (0.20%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $10.12 -0.01 (-0.10%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
iTeos Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ITOS 10.13 +0.02(0.20%)
Will ITOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITOS
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
ITOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
Other News for ITOS
Wells Fargo Lowers Price Target for ITeos Therapeutics (ITOS) to $11.00 | ITOS Stock News
Ridgeback Capital Investments L.P. Acquires Significant Stake in ITeos Therapeutics Inc.
iTeos Therapeutics (ITOS) Downgraded Following Merger Agreement | ITOS Stock News
iTeos Therapeutics just downgraded at Piper Sandler, here's why
iTeos Therapeutics (ITOS) Agrees to Acquisition by Concentra Biosciences